Cargando…

A feasibility service evaluation of screening and treatment of group A streptococcal pharyngitis in community pharmacies

OBJECTIVES: The UK 5 year antimicrobial resistance strategy recognizes the role of point-of-care diagnostics to identify where antimicrobials are required, as well as to assess the appropriateness of the diagnosis and treatment. A sore throat test-and-treat service was introduced in 35 community pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Thornley, T., Marshall, G., Howard, P., Wilson, A. P. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5079295/
https://www.ncbi.nlm.nih.gov/pubmed/27439523
http://dx.doi.org/10.1093/jac/dkw264
_version_ 1782462538564239360
author Thornley, T.
Marshall, G.
Howard, P.
Wilson, A. P. R.
author_facet Thornley, T.
Marshall, G.
Howard, P.
Wilson, A. P. R.
author_sort Thornley, T.
collection PubMed
description OBJECTIVES: The UK 5 year antimicrobial resistance strategy recognizes the role of point-of-care diagnostics to identify where antimicrobials are required, as well as to assess the appropriateness of the diagnosis and treatment. A sore throat test-and-treat service was introduced in 35 community pharmacies across two localities in England during 2014–15. METHODS: Trained pharmacy staff assessed patients presenting with a sore throat using the Centor scoring system and patients meeting three or all four of the criteria were offered a throat swab test for Streptococcus pyogenes, Lancefield group A streptococci. Patients with a positive throat swab test were offered antibiotic treatment. RESULTS: Following screening by pharmacy staff, 149/367 (40.6%) patients were eligible for throat swab testing. Of these, only 36/149 (24.2%) were positive for group A streptococci. Antibiotics were supplied to 9.8% (n = 36/367) of all patients accessing the service. Just under half of patients that were not showing signs of a bacterial infection (60/123, 48.8%) would have gone to their general practitioner if the service had not been available. CONCLUSIONS: This study has shown that it is feasible to deliver a community-pharmacy-based screening and treatment service using point-of-care testing. This type of service has the potential to support the antimicrobial resistance agenda by reducing unnecessary antibiotic use and inappropriate antibiotic consumption.
format Online
Article
Text
id pubmed-5079295
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-50792952016-10-26 A feasibility service evaluation of screening and treatment of group A streptococcal pharyngitis in community pharmacies Thornley, T. Marshall, G. Howard, P. Wilson, A. P. R. J Antimicrob Chemother Original Research OBJECTIVES: The UK 5 year antimicrobial resistance strategy recognizes the role of point-of-care diagnostics to identify where antimicrobials are required, as well as to assess the appropriateness of the diagnosis and treatment. A sore throat test-and-treat service was introduced in 35 community pharmacies across two localities in England during 2014–15. METHODS: Trained pharmacy staff assessed patients presenting with a sore throat using the Centor scoring system and patients meeting three or all four of the criteria were offered a throat swab test for Streptococcus pyogenes, Lancefield group A streptococci. Patients with a positive throat swab test were offered antibiotic treatment. RESULTS: Following screening by pharmacy staff, 149/367 (40.6%) patients were eligible for throat swab testing. Of these, only 36/149 (24.2%) were positive for group A streptococci. Antibiotics were supplied to 9.8% (n = 36/367) of all patients accessing the service. Just under half of patients that were not showing signs of a bacterial infection (60/123, 48.8%) would have gone to their general practitioner if the service had not been available. CONCLUSIONS: This study has shown that it is feasible to deliver a community-pharmacy-based screening and treatment service using point-of-care testing. This type of service has the potential to support the antimicrobial resistance agenda by reducing unnecessary antibiotic use and inappropriate antibiotic consumption. Oxford University Press 2016-11 2016-07-20 /pmc/articles/PMC5079295/ /pubmed/27439523 http://dx.doi.org/10.1093/jac/dkw264 Text en © The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Research
Thornley, T.
Marshall, G.
Howard, P.
Wilson, A. P. R.
A feasibility service evaluation of screening and treatment of group A streptococcal pharyngitis in community pharmacies
title A feasibility service evaluation of screening and treatment of group A streptococcal pharyngitis in community pharmacies
title_full A feasibility service evaluation of screening and treatment of group A streptococcal pharyngitis in community pharmacies
title_fullStr A feasibility service evaluation of screening and treatment of group A streptococcal pharyngitis in community pharmacies
title_full_unstemmed A feasibility service evaluation of screening and treatment of group A streptococcal pharyngitis in community pharmacies
title_short A feasibility service evaluation of screening and treatment of group A streptococcal pharyngitis in community pharmacies
title_sort feasibility service evaluation of screening and treatment of group a streptococcal pharyngitis in community pharmacies
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5079295/
https://www.ncbi.nlm.nih.gov/pubmed/27439523
http://dx.doi.org/10.1093/jac/dkw264
work_keys_str_mv AT thornleyt afeasibilityserviceevaluationofscreeningandtreatmentofgroupastreptococcalpharyngitisincommunitypharmacies
AT marshallg afeasibilityserviceevaluationofscreeningandtreatmentofgroupastreptococcalpharyngitisincommunitypharmacies
AT howardp afeasibilityserviceevaluationofscreeningandtreatmentofgroupastreptococcalpharyngitisincommunitypharmacies
AT wilsonapr afeasibilityserviceevaluationofscreeningandtreatmentofgroupastreptococcalpharyngitisincommunitypharmacies
AT thornleyt feasibilityserviceevaluationofscreeningandtreatmentofgroupastreptococcalpharyngitisincommunitypharmacies
AT marshallg feasibilityserviceevaluationofscreeningandtreatmentofgroupastreptococcalpharyngitisincommunitypharmacies
AT howardp feasibilityserviceevaluationofscreeningandtreatmentofgroupastreptococcalpharyngitisincommunitypharmacies
AT wilsonapr feasibilityserviceevaluationofscreeningandtreatmentofgroupastreptococcalpharyngitisincommunitypharmacies